Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Authors
Keywords
-
Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-07-12
DOI
10.1002/jlb.5ri0218-084r
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
- (2018) H. Nakagawa et al. BRITISH JOURNAL OF DERMATOLOGY
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
- (2018) Anna Sophia McKenney et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
- (2018) Michael L. Vazquez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
- (2017) Gabriela S. Hobbs et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Group 1 Innate Lymphoid Cell Lineage Identity Is Determined by a cis -Regulatory Element Marked by a Long Non-coding RNA
- (2017) Walter K. Mowel et al. IMMUNITY
- A Case Series on Patients on Tofacitinib in Combination With a Biologic
- (2017) Nashla S. Barroso et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Subset- and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells
- (2017) Alejandro V. Villarino et al. JOURNAL OF EXPERIMENTAL MEDICINE
- STAT5B: A Differential Regulator of the Life and Death of CD4+Effector Memory T Cells
- (2017) Sonia S. Majri et al. JOURNAL OF IMMUNOLOGY
- Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy
- (2017) David T. Beattie et al. Journal of Inflammation-London
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
- (2017) Peter Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
- (2017) Fiona Elwood et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
- (2017) Edward C. Keystone et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Janus kinase inhibitors in dermatology: A systematic review
- (2017) Rony Shreberk-Hassidim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A phase 1 study of the Janus kinase 2 ( JAK2 ) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
- (2017) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Jak3 deficiency blocks innate lymphoid cell development
- (2017) M L Robinette et al. Mucosal Immunology
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
- (2017) Davide Genini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study
- (2017) Satoshi Kubo et al. RHEUMATOLOGY
- Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study
- (2017) Kensuke Kume et al. RHEUMATOLOGY INTERNATIONAL
- Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis
- (2017) T Komai et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Type I Interferon in Chronic Virus Infection and Cancer
- (2017) Laura M. Snell et al. TRENDS IN IMMUNOLOGY
- Responses to Cytokines and Interferons that Depend upon JAKs and STATs
- (2017) George R. Stark et al. Cold Spring Harbor Perspectives in Biology
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
- (2017) Christina Gavegnano et al. PLoS Pathogens
- Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci
- (2017) Laura A. McIntosh et al. Arthritis & Rheumatology
- The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Role of Type I and II Interferons in Colorectal Cancer and Melanoma
- (2017) Simone Di Franco et al. Frontiers in Immunology
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
- (2016) Andy J. Minn et al. CELL
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- Mitochondrial STAT3: Powering up a potent factor
- (2016) Daniel J. Garama et al. CYTOKINE
- Emancipation from transcriptional latency: unphosphorylated STAT5 as guardian of hematopoietic differentiation
- (2016) Thomas Decker EMBO JOURNAL
- Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8 + T Cells
- (2016) Sarah H. Ross et al. IMMUNITY
- Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children
- (2016) Marie-Louise Frémond et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Evolution of Cytokine Receptor Signaling
- (2016) Clifford Liongue et al. JOURNAL OF IMMUNOLOGY
- Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
- (2016) Geoffrey A Smith et al. Nature Chemical Biology
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
- (2016) Vibeke Strand et al. RHEUMATOLOGY
- Trisomy 21 consistently activates the interferon response
- (2016) Kelly D Sullivan et al. eLife
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- Molecular mechanisms of pruritus
- (2016) J. Meng et al. Current Research in Translational Medicine
- THU0174 Analysis of Non-melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Programme
- (2015) J. Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study:
- (2015) M.C. Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0349 Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Tumor Necrosis Factor Inhibitors: Table 1
- (2015) J.S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Gone fission: an asymptomaticSTAT2mutation elongates mitochondria and causes human disease following viral infection
- (2015) Asish Dasgupta et al. BRAIN
- The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
- (2015) S J Thomas et al. BRITISH JOURNAL OF CANCER
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
- (2015) Sara C. Meyer et al. CANCER CELL
- Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
- (2015) Shuo-Chieh Wu et al. CANCER CELL
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
- (2015) Michinori Ogura et al. CANCER SCIENCE
- Tofacitinib for the treatment of moderate-to-severe psoriasis
- (2015) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
- (2015) R Zeiser et al. LEUKEMIA
- Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
- (2015) Lara Brambilla et al. Molecular Oncology
- The selection and function of cell type-specific enhancers
- (2015) Sven Heinz et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
- (2015) G Montealegre et al. Pediatric Rheumatology
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Super-enhancers: Asset management in immune cell genomes
- (2015) Steven Witte et al. TRENDS IN IMMUNOLOGY
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
- (2015) Vijay U. Rao et al. Arthritis & Rheumatology
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- (2015) S. Harel et al. Science Advances
- The molecular regulation of Janus kinase (JAK) activation
- (2014) Jeffrey J. Babon et al. BIOCHEMICAL JOURNAL
- Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
- (2014) J. D. Milner et al. BLOOD
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Selective JAK inhibitors in development for rheumatoid arthritis
- (2014) Peter Norman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Intravenous golimumab in rheumatoid arthritis
- (2014) Marc D Cohen et al. Expert Review of Clinical Immunology
- Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis
- (2014) Lindsey A. MacFarlane et al. International Journal of Rheumatic Diseases
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease
- (2014) Sarah E Flanagan et al. NATURE GENETICS
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Toward a new STATe: The role of STATs in mitochondrial function
- (2014) Jeremy A. Meier et al. SEMINARS IN IMMUNOLOGY
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
- (2013) Mi-Jung Kim et al. CANCER LETTERS
- Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome
- (2013) Gulbu Uzel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
- (2013) Naoko Okiyama et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
- (2013) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAT2 deficiency and susceptibility to viral illness in humans
- (2013) S. Hambleton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci
- (2012) David Ellinghaus et al. AMERICAN JOURNAL OF HUMAN GENETICS
- U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
- (2012) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- Janus Kinase Deregulation in Leukemia and Lymphoma
- (2012) Edwin Chen et al. IMMUNITY
- Inborn Errors of Human JAKs and STATs
- (2012) Jean-Laurent Casanova et al. IMMUNITY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Targeting IL-17 and TH17 cells in chronic inflammation
- (2012) Pierre Miossec et al. NATURE REVIEWS DRUG DISCOVERY
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
- (2012) Malabika Sen et al. Cancer Discovery
- Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen
- (2011) B. C. Betts et al. BLOOD
- FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
- (2011) N. E. Elliott et al. BLOOD
- Dynamics and non-canonical aspects of JAK/STAT signalling
- (2011) Anne Mohr et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans
- (2011) Gabriela Schmajuk et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Differentiation of Effector CD4 T Cell Populations
- (2010) Jinfang Zhu et al. Annual Review of Immunology
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
- (2010) Andre Franke et al. NATURE GENETICS
- Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival
- (2010) T. W. Hand et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CP-690550, a Janus Kinase Inhibitor, Suppresses CD4+ T-Cell–Mediated Acute Graft-Versus-Host Disease by Inhibiting the Interferon-γ Pathway
- (2010) Hyung-Bae Park et al. TRANSPLANTATION
- Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study inDe NovoKidney Allograft Recipients
- (2009) S. Busque et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
- (2009) J H Coombs et al. ANNALS OF THE RHEUMATIC DISEASES
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
- (2009) Ana L. Basquiera et al. Hematology
- JAK mutations in high-risk childhood acute lymphoblastic leukemia
- (2009) C. G. Mullighan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- ITP three R's: regulation, routing, rituximab
- (2008) J. W. Semple BLOOD
- Mining for JAK–STAT mutations in cancer
- (2008) Stefan N. Constantinescu et al. TRENDS IN BIOCHEMICAL SCIENCES
- A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
- (2008) Allison L Smitten et al. ARTHRITIS RESEARCH & THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started